Nxera Pharma CoSOLTF 84 FCF Yield % is -12.24 as of Jun. 27, 2026. GuruFocus rates SOLTF with a GF Score™ of 84/100 and a GF Value™ of $7.79 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,418 Biotechnology companies, Nxera Pharma Co ranks worse than 55.92% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Nxera Pharma Co FCF Yield % Related Terms
Nxera Pharma Co FCF Yield % Historical Data
* Premium members only.
The historical data trend for Nxera Pharma Co's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nxera Pharma Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nxera Pharma Co FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Nxera Pharma Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nxera Pharma Co (SOLTF) has a FCF Yield % of -12.24 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Nxera Pharma Co and its competitors. According to the industry distribution chart, Nxera Pharma Co ranks #793 out of 1418 companies in the Biotechnology industry, placing it in the top 55.9%.
Is Nxera Pharma Co's FCF Yield % too high?
Nxera Pharma Co's current FCF Yield % is -12.24. Based on the distribution chart, Nxera Pharma Co ranks #793 out of 1418 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nxera Pharma Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nxera Pharma Co ranks #793 out of 1418 companies for FCF Yield %. This places Nxera Pharma Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Nxera Pharma Co and its competitors. Nxera Pharma Co's current FCF Yield % is -12.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Nxera Pharma Co (SOLTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.79, compared to a current price of $6.37 — trading 18.2% below its estimated fair value. The current FCF Yield % is -12.24. Nxera Pharma Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Nxera Pharma Co (SOLTF), the current FCF Yield % is -12.24 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nxera Pharma Co (SOLTF) Overvalued in 2026?
Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued.
The current stock price of $6.37 is trading 18.2% below its estimated GF Value™ of $7.79.
GuruFocus considers Nxera Pharma Co to be Modestly Undervalued.
Key valuation signals for SOLTF:
FCF Yield %: -12.24
GF Value™: $7.79 vs. price of $6.37 (18.2% below fair value)
No single metric tells the full story. See the SOLTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
84GF Score
Get the complete analysis for SOLTF
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOLTF has been successfully added to your 
